As Seen In

As Seen In

VP Lee Buckler Podcast Interview by Midas Letter

Written By: James West

Listen to the full interview here.

RepliCel’s VP Lee Buckler explains the excitement among company stakeholders surrounding upcoming trials of RepliCel’s autologous cell therapy approach to chronic Achilles tendinosis, and other catalysts in 2015. RepliCel received Health Canada approval for the clinical trial to go forward on December 1st, 2014.

The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.